BioSpace News Archive

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will present at the H.C. Wainwright BioConnect Conference.

NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that it will present a company overview at the upcoming Biotech Showcase conference.

Transcat, Inc., a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it has purchased all of the stock of privately-held Tangent Labs, LLC, effective December 31, 2021.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for the CM-1600, its next generation fluid monitoring system.

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is scheduled to participate in the following investor conferences in January 2022.

Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain, announced that new Category I Current Procedural Terminology codes for the Intracept Procedure are in effect as of January 1, 2022.

Sin Hang Lee, MD is offering a diagnostic test directly to patients and their healthcare providers, a test that can determine all known COVID-19 variants of concern and interest, including the Omicron and Delta strains, the most predominant strains in the United States.

Kyverna Therapeutics today announced that the company has entered into exclusive, worldwide licenses with the National Institutes of Health (NIH) for intellectual property related to a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties uniquely suited for use in autoimmune diseases.

Company to Conduct Virtual One-on-One Meetings During Biotech Showcase.

According to Emergen Research, the global drug screening market size was USD 3.83 Billion in 2019 and is expected to reach USD 13.56 Billion in 2027 and register a revenue CAGR of 17.1% during the forecast period, 2020-2027.